The prospective French participitation to IDEA (International Duration Evaluation of Adjuvant Chemotherapy) study in stage III colon cancer: Patients' characteristics and safety analysis of 3 versus 6 months of adjuvant chemotherapy.

被引：0
|
作者：
Andre, Thierry
De Gramont, Aimery
Mineur, Laurent
Desrame, Jerome
Faroux, Roger
Bennouna, Jaafar
Dauba, Jerome
Louvet, Christophe
Pernot, Simon
Dupuis, Olivier Jean Marie
Becouarn, Yves
Mabro, May
Egreteau, Joelle
Bouche, Olivier
Bonnetain, Franck
de larauze, Marine Hug
Le Malicot, Karine
Taieb, Julien
机构：
[1] Hop St Antoine, F-75571 Paris, France
[2] Inst Hosp Franco Britann, Levallois Perret, France
[3] Inst St Catherine, Avignon, France
[4] Hop Prive Jean Mermoz, Lyon, France
[5] Ctr Hosp Dept Oudairies, La Roche Sur Yon, France
[6] Inst Cancerol Ouest, Nantes, France
[7] Ctr Hosp Layne, Mt De Marsan, France
[8] Inst Mutualiste Montsouris, Paris, France
[9] Hop Europeen Georges Pompidou, Paris, France
[10] Clin Victor Hugo, Le Mans, France
[11] Inst Bergonie, Bordeaux, France
[12] Hop Foch, Suresnes, France
[13] Ctr Hosp Bretagne Sud, Lorient, France
[14] Ctr Hosp Univ Robert Debre, Reims, France
[15] Ctr Hosp Reg & Univ, Besancon, France
[16] GERCOR, Paris, France
[17] FFCD, Dijon, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 04期
关键词：
D O I：
10.1200/jco.2016.34.4_suppl.633
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
633
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Evaluation of a 55-gene classifier as a prognostic biomarker for adjuvant chemotherapy in stage III colon cancer patients
    Eiji Oki
    Eiji Shinto
    Mototsugu Shimokawa
    Shigeki Yamaguchi
    Megumi Ishiguro
    Seiji Hasegawa
    Yasumasa Takii
    Hideyuki Ishida
    Tetsuya Kusumoto
    Masaru Morita
    Naohiro Tomita
    Manabu Shiozawa
    Masafumi Tanaka
    Heita Ozawa
    Yojiro Hashiguchi
    Shinobu Ohnuma
    Sachiyo Tada
    Tomoko Matsushima
    Kazuo Hase
    BMC Cancer, 21
  • [42] Three-versus six-month adjuvant FOLFOX or CAPOX for high-risk stage II and stage III colon cancer patients: the efficacy results of Hellenic Oncology Research Group (HORG) participation to the International Duration Evaluation of Adjuvant Chemotherapy (IDEA) project
    Souglakos, J.
    Boukovinas, I
    Kakolyris, S.
    Xynogalos, S.
    Ziras, N.
    Athanasiadis, A.
    Androulakis, N.
    Christopoulou, A.
    Vaslamatzis, M.
    Ardavanis, A.
    Emmanouilides, C.
    Bompolaki, I
    Kourousis, C.
    Makrantonakis, P.
    Christofyllakis, C.
    Athanasiadis, E.
    Kentepozidis, N.
    Karampeazis, A.
    Katopodi, U.
    Anagnosopoulos, A.
    Papadopoulos, G.
    Prinarakis, E.
    Kalisperi, A.
    Mavroudis, D.
    Georgoulias, V
    ANNALS OF ONCOLOGY, 2019, 30 (08) : 1304 - 1310
  • [43] Patients' Preferences for 3 Versus 6 Months of Adjuvant Chemotherapy (ACT) for Colon Cancer in the SCOT Trial: What Survival Benefits Make Longer Chemotherapy Worthwhile?
    Blinman, P.
    Martin, A.
    Jefford, M.
    Goldstein, D.
    Boadle, D.
    Morris, M.
    Tebbutt, N.
    Aiken, C.
    Segelov, E.
    Paul, J.
    Haydon, A.
    Iveson, T.
    Stockler, M.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 : 51 - 51
  • [44] Self-evaluation of duration of adjuvant chemotherapy side effects in breast cancer patients: A prospective study
    Galizia, Danilo
    Milani, Andrea
    Geuna, Elena
    Martinello, Rossella
    Cagnazzo, Celeste
    Foresto, Manuela
    Longo, Virginia
    Berchialla, Paola
    Solinas, Gianfranca
    Calori, Adele
    Grasso, Bruna
    Volpone, Chiara
    Bertola, Gisella
    Parola, Gisella
    Tealdi, Giancarla
    Giuliano, Piero Luigi
    Ballari, Anna Maria
    Aglietta, Massimo
    Montemurro, Filippo
    CANCER MEDICINE, 2018, 7 (09): : 4339 - 4344
  • [45] Self-evaluation of duration of adjuvant chemotherapy side effects in breast cancer patients: A prospective study
    Galizia, D.
    Martinello, R.
    Cagnazzo, C.
    Foresto, M.
    Gallizioli, S.
    Longo, V.
    Berchialla, P.
    Solinas, G.
    Calori, A.
    Volpone, C.
    Parola, G.
    Tealdi, G.
    Ballari, A.
    Montemurro, F.
    CANCER RESEARCH, 2017, 77
  • [46] Efficacy of oxaliplatin-based adjuvant chemotherapy in older patients with stage III colon cancer: An ACCENT/IDEA pooled analysis of 12 trials
    Gallois, C.
    Shi, Q.
    Meyers, J.
    Andre, T.
    Iveson, T. J.
    Sobrero, A. F.
    Alberts, S.
    de Gramont, A.
    Meyerhardt, J.
    Shields, A. F.
    Georges, T.
    Schmoll, H. J. E-V.
    Souglakos, I.
    Kerr, R.
    Lonardi, S.
    Yothers, G.
    Yoshino, T.
    Goldberg, R.
    Taieb, J.
    Papamichael, D.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S682 - S683
  • [47] Duration of oxaliplatin-based adjuvant chemotherapy in patients with Stage III or high-risk Stage II resected colon cancer
    Moretto, Roberto
    Falcone, Alfredo
    Cremolini, Chiara
    INTERNATIONAL JOURNAL OF CANCER, 2020, 146 (09) : 2652 - 2654
  • [48] Use of adjuvant chemotherapy in patients with stage III colon cancer in Puerto Rico: A population-based study
    Ortiz-Ortiz, Karen J.
    Tortolero-Luna, Guillermo
    Rios-Motta, Ruth
    Veintidos-Feli, Alejandro
    Hunter-Mellado, Robert
    Torres-Cintron, Carlos R.
    Suarez-Ramos, Tonatiuh
    Magno, Priscilla
    PLOS ONE, 2018, 13 (03):
  • [49] Efficacy and Toxicity of Adjuvant FOLFOX Chemotherapy in Elderly Patients With Stage III Colon Cancer - Single Center Study
    Kim, J. Y.
    Kim, Y. J.
    Lee, K. W.
    Kim, D. W.
    Lee, H. S.
    Kim, J. S.
    Kang, S. B.
    Lee, J. S.
    Kim, J. H.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S279 - S279
  • [50] Lymphovascular invasion represents a superior prognostic and predictive pathological factor of the duration of adjuvant chemotherapy for stage III colon cancer patients
    Zhang, Linjie
    Deng, Yuxiang
    Liu, Songran
    Zhang, Weili
    Hong, Zhigang
    Lu, Zhenhai
    Pan, Zhizhong
    Wu, Xiaojun
    Peng, Jianhong
    BMC CANCER, 2023, 23 (01)
12345